Drugs that contain Suvorexant

1. Belsomra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-253) Jan 29, 2023
New Chemical Entity Exclusivity(NCE) Aug 13, 2019

NCE-1 date: 13 August, 2018

Market Authorisation Date: 13 August, 2014

Treatment: Treatment of insomnia


More Information on Dosage

BELSOMRA family patents

Family Patents